# Efficacy, Safety and Tolerability of AFQ056 in Fragile X Patients

> **NCT00718341** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 30 (actual)

## Conditions studied

- Fragile X Syndrome

## Interventions

- **DRUG:** AF056
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00718341
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-02
- **Final completion:** —
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00718341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00718341, "Efficacy, Safety and Tolerability of AFQ056 in Fragile X Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00718341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*